TOI Reports Q2 Revenue Growth and Positive Adjusted EBITDA, Rebrands to Starling Oncology

What happened

The Oncology Institute (TOI) delivered Q2 revenue growth and, critically, positive adjusted EBITDA, beating the breakeven target set after its refinancing. The company also announced an expanded pipeline of value-based oncology contracts and a rebranding to Starling Oncology, signaling a strategic emphasis on its delegated-risk, pharmacy-integrated model. This quarter’s profitability milestone marks the first concrete step toward self-funded operations, a key requirement after the July 2026 term loan removed the near-term debt maturity overhang. The positive earnings surprise and contract momentum directly address earlier concerns about the Florida Medicare Advantage expansion translating into margin improvement. While cash flow remains the next critical hurdle, the Q2 print raises the probability that TOI can achieve its full-year free cash flow guidance and trade toward the upper end of its valuation range.

Implication

Investors should take the positive adjusted EBITDA as confirmation that TOI’s operating leverage is finally materializing, driven by pharmacy volume growth and value-based contract ramp. The rebranding to Starling Oncology is likely a cosmetic move but may help recast the company as a mature platform rather than a struggling roll-up. With the balance sheet restructured, the immediate risk of a capital raise has receded; attention now turns to whether Q3 can deliver positive operating cash flow. The stock’s risk/reward improves, though the $700 million revenue covenant for December 2027 still looms if growth decelerates. At current prices, the potential re-rating toward the low end of the bull case ($7.20) becomes more plausible if the company sustains EBITDA profitability for another quarter.

Thesis delta

The thesis strengthens as Q2’s positive adjusted EBITDA confirms progress toward self-funding, a core requirement. However, the transformation is not yet complete, with positive operating cash flow and covenant compliance remaining as the next proofs. The conviction rating edges up but the base-case scenario probability increases, aligning the stock more closely with its upside target.